Team,
Here is the claim I am willing to defend.
Menopause is a neurological event that happens to involve the ovaries. Not the other way around.
The brain is the first organ affected by falling estrogen, not the last. And the medical system is still treating it as a gynecological problem with some annoying cognitive side effects, which is why a 44-year-old woman describing brain fog is far more likely to leave her appointment with an antidepressant than a neurological workup.
I made this episode because of one number that reframes the entire debate: women who started hormone therapy within five years of menopause had substantially lower Alzheimer’s risk. Women who started after 65 had higher risk. Same therapy. Opposite outcomes. The only variable was when they began.
That is not a nuance. That is a fork in the road, and most women are being walked past it without being told it exists.
TOPICS DISCUSSED
00:00 – Cold open: bold claims & who is Sam Bertram
00:51 – Why vertical farms collapse (Bowery) & how OnePointOne survived
05:49 – The number that started it all: 1.1 billion malnourished
07:30 – Why micronutrient deficiency is the real killer
08:21 – What OnePointOne actually is: "a box that grows plants"
10:03 – Training plants with light & water to boost nutrients
11:00 – Closing the loop: food matched to your body's data
12:28 – The plan for 1,000 farms & the AutoStore partnership
15:46 – Plant biology 101: growing with no soil, no sun
18:11 – The robots — and why humans are still essential
21:27 – Pesticides, washing produce & disease clusters
23:53 – Beet greens for cancer patients & the Whole Foods deal
24:42 – A 13-person company run on AI
25:15 – The 15-day crop & cracking the cost code
27:11 – Biology vs. software: what really makes it work
28:01 – Humanoid robots, ~5 years away
30:27 – Why raise $80M and not $500M
33:56 – What they do to a plant that nature never would
36:28 – Expanding crops: strawberries, cannabis, mushrooms
38:05 – Growing food & materials in space (Elon, text back)
39:38 – Personalized food grown from your blood test
40:24 – Food as medicine & the truth about Western medicine
41:11 – Sam's mystery illness: 8 years without exercise
44:23 – Plants as medicine — who "fed and dosed" the world?
49:32 – Manufacturing pharmaceutical molecules inside plants
50:18 – Replicating $30–40k drugs cheaply (Rituximab, Lecanemab)
54:21 – Why the Middle East may beat the US, RFK Jr & MAHA
55:11 – Genetics, cancer & the healthy 80–90%
57:35 – Taste: beating junk food at its own game
58:27 – Why good food got so expensive (money printing)
59:14 – A world without hunger — how far away?
1:00:24 – Tasting the farm: microgreens, bok choy, mizuna & kale
The estrogen shield
Most women are taught that estrogen is a reproductive hormone. It is also the most important neuroprotective molecule in the female brain, and it does four things nothing else does: it drives mitochondrial energy production in neurons, it pushes amyloid processing down the clean pathway instead of the toxic one, it upregulates antioxidant defense, and it maintains white matter integrity.
Then, over the menopause transition, it drops by roughly 80%.
Mosconi’s 2021 imaging work in Scientific Reports found menopause status was a stronger predictor of Alzheimer’s brain changes in women than age or family history. That is the finding that should have changed clinical practice and has not.
The twenty-year head start
The silent phase of Alzheimer’s begins two to three decades before symptoms. In women, that window overlaps almost exactly with perimenopause.
Which means the brain fog you are dismissing as burnout is happening at the same moment the pathology is forming. Not causally identical, but not unrelated either.
The part that makes me angry is the diagnostic gap. Women presenting with cognitive symptoms are more likely to be assessed for depression than investigated neurologically. By the time anyone looks properly, years have passed.
The hormone window
A meta-analysis presented at the 2025 American Neurological Association meeting found HRT initiated within five years of menopause was associated with up to 32% lower Alzheimer’s risk. Initiated after 65: 38% higher.
The mechanism explains the timing. During perimenopause and early postmenopause the brain’s estrogen receptors are still functional. Reintroduce estrogen and the signaling machinery responds. Wait a decade and neurons that have been starved of that signal do not respond the same way.
And in the EPAD cohort, women carrying APOE4, the ones at highest genetic risk, showed the largest benefit from early initiation.
I am not a prescribing physician and I am not telling you to take anything. I am telling you that the conversation you have at 42 is a different conversation than the one you have at 68, and that a lot of clinicians are still working from the 2002 WHI framing that has since been reanalyzed. If your doctor has not read anything published after 2002, find one who has.
The honest caveat: this is observational and conference-presented, not a completed randomized trial in perimenopausal women. The timing hypothesis is well supported. It is not settled. Anyone selling you certainty here is selling you something.
The rest
Three more layers in the full episode: why resistance training produces the irisin-BDNF cascade without the cortisol cost, why the glymphatic system only clears amyloid during deep slow-wave sleep and why perimenopausal women lose that stage disproportionately, and why cortisol is the thread running through every other mechanism.
The woman I worry about most in clinical work is the one doing everything right. Running a business, training hard five days a week, sleeping six hours, skipping meals. She is elevating cortisol in every domain simultaneously and she thinks she is being healthy.
Full episode out now.
This newsletter is brought to you by Function Health
Real question.
When was the last time you looked beyond how you feel and actually measured your health?
Not guessed. Not assumed. Measured.
Many of the biological changes that increase the risk of cardiovascular disease, metabolic dysfunction, and other chronic conditions begin years before symptoms appear.
That’s why biomarkers matter.
Apolipoprotein B (ApoB), non-HDL cholesterol, and Lipoprotein(a) [Lp(a)] provide a more comprehensive picture of atherosclerotic cardiovascular risk than LDL cholesterol alone in many people.
Fasting glucose, HbA1c, fasting insulin, and the triglyceride-to-HDL ratio can help assess glucose regulation, insulin sensitivity, and overall metabolic health.
High-sensitivity C-reactive protein (hs-CRP), creatinine, estimated glomerular filtration rate (eGFR), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), and the urine albumin-to-creatinine ratio (UACR) offer valuable insight into systemic inflammation, kidney health, liver function, and early vascular damage.
No single biomarker tells the whole story. Together, they help establish a baseline, monitor trends over time, and identify opportunities for earlier intervention.
That’s one reason I like Function Health.
With 160+ lab tests annually, it provides a broad snapshot of key physiological systems, helping you make more informed decisions about nutrition, exercise, recovery, and long-term health.
You can’t optimize what you don’t measure.
If you’re serious about improving your healthspan, reducing preventable risk, and making decisions based on data instead of guesswork, Function Health is a great place to start.
Check it out and use my code below.
